Related Experiment Videos
Individual changes in lamotrigine plasma concentrations during pregnancy
Vaiva Petrenaite1, Anne Sabers, Jacob Hansen-Schwartz
1Department of Clinical Neurophysiology 3063, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. vaiva@ofir.dk
Epilepsy Research
|August 9, 2005
Summary
Pregnancy significantly reduces lamotrigine (LTG) levels in the blood, increasing seizure risk. Close monitoring of LTG concentrations is crucial for pregnant women to ensure treatment efficacy and safety.
Area of Science:
- Pharmacology
- Obstetrics
- Neurology
Background:
- Lamotrigine (LTG) is an antiepileptic drug used in pregnancy.
- Pregnancy is known to alter drug pharmacokinetics.
- Limited data exists on LTG pharmacokinetics during pregnancy.
Purpose of the Study:
- To investigate changes in lamotrigine plasma concentration-to-dose ratio during pregnancy.
- To assess the impact of these changes on seizure control.
Main Methods:
- Retrospective review of 11 pregnant women on lamotrigine monotherapy.
- Comparison of lamotrigine levels pre-pregnancy versus during the second and third trimesters.
Main Results:
- A significant decrease of 65.1% in LTG concentration-to-dose ratio during the second trimester (p=0.0058).
- A significant decrease of 65.8% in LTG concentration-to-dose ratio during the third trimester (p=0.0045).
- Five patients experienced seizure deterioration during pregnancy.
Conclusions:
- Pregnancy causes substantial reductions in lamotrigine levels.
- Inter-patient variability in pharmacokinetic changes is significant.
- Individualized monitoring of lamotrigine levels is essential throughout pregnancy.